The recent advances in our understanding of the molecular basis for a broad range of pediatric diseases, coupled with the legislative changes culminating in the Best Pharmaceuticals for Children Act, has dramatically increased the potential for defining novel therapeutic approaches for a spectrum of childhood diseases. Further, it provides an important opportunity for improving our understanding of how best to utilize medications currently available for children. The Children's Hospital of Philadelphia (CHOP) has the necessary research infrastructure, patient population, and clinical and laboratory expertise to continue its participation and leadership in the Pediatric Pharmacology Research Unit (PPRU) Network. Under the PI leadership of a Board-certified clinical pharmacologist over the past 4 years, the CHOP PPRU experienced impressive growth both in patient accrual to studies and in the development of industry sponsored trials for Network participation. The CHOP PPRU's recruitment of an internationally renowned population pharmacokinetic modeler further increases the depth and strength of this program. The core laboratory has an in depth experience with state-of-the-art analytical techniques allowing for analysis of a broad spectrum of drugs in biologic matrices, each performed according to FDA's Good Laboratory Practices (GLP) specifications. Novel analytical methodologies developed by the CHOP PPRU will allow for ongoing genotype-phenotype correlative studies. The recent establishment of a proteomics core further expands upon these research capabilities. The CHOP PPRU will continue to emphasize clinical pharmacologic trials in the immunocompromised host, the critically ill infant and child, and in pediatric pain management. Two protocols developed for the PPRU Network, """"""""A Pediatric Phase 1 Trial, and Pharmacokinetic, Pharmacogenetic and Pharmacodynamic Study of Dexmedetomidine"""""""" and """"""""A Pediatric Population Pharmacokinetic Study of Heparin: Clinical Utility of Exposure and Biomarkers of Anticoagulation"""""""" are proposed and highlight CHOP's PPRU scientific focus. Our expertise in drug analytical methods, pharmacokinetic modeling, pharmacogenomics and proteomics, combined with unparalleled pediatric clinical expertise and access to a diverse pediatric population, assure the continued successful participation of the CHOP PPRU in collaborative Network research.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10HD037255-06
Application #
6729594
Study Section
Special Emphasis Panel (ZHD1-DSR-A (01))
Program Officer
Giacoia, George
Project Start
1999-01-07
Project End
2008-12-31
Budget Start
2004-02-15
Budget End
2004-12-31
Support Year
6
Fiscal Year
2004
Total Cost
$364,975
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
McCune, Jeannine S; Bemer, Meagan J; Barrett, Jeffrey S et al. (2014) Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res 20:754-63
Su, Felice; Nicolson, Susan C; Zuppa, Athena F (2013) A dose-response study of dexmedetomidine administered as the primary sedative in infants following open heart surgery. Pediatr Crit Care Med 14:499-507
McCune, Jeannine S; Baker, K Scott; Blough, David K et al. (2013) Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. J Clin Pharmacol 53:264-75
Piper, Lauren; Smith, P Brian; Hornik, Christoph P et al. (2011) Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J 30:375-8
Dombrowsky, Erin; Jayaraman, Bhuvana; Narayan, Mahesh et al. (2011) Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit 33:99-107
Barrett, Jeffrey S; Narayan, Mahesh; Patel, Dimple et al. (2011) Prescribing habits and caregiver satisfaction with resources for dosing children: rationale for more informative dosing guidance. BMC Pediatr 11:25
Su, Felice; Nicolson, Susan C; Gastonguay, Marc R et al. (2010) Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. Anesth Analg 110:1383-92
Wu, Di; Wade, Kelly C; Paul, Dustin J et al. (2009) A rapid and sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with Candida infections. Ther Drug Monit 31:703-9
Wade, Kelly C; Benjamin Jr, Daniel K; Kaufman, David A et al. (2009) Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 28:717-23
Cohen-Wolkowiez, M; Smith, P B; Benjamin Jr, D K et al. (2008) Daptomycin use in infants: report of two cases with peak and trough drug concentrations. J Perinatol 28:233-4

Showing the most recent 10 out of 13 publications